MedPath

Expanded Access for IMMU-132

Conditions
Metastatic Triple-Negative Breast Carcinoma
Registration Number
NCT04320693
Lead Sponsor
Gilead Sciences
Brief Summary

This is an expanded access program (EAP) for eligible participants designed to provide access to IMMU-132.

Detailed Description

Not available

Recruitment & Eligibility

Status
APPROVED_FOR_MARKETING
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
Exclusion Criteria

Study & Design

Study Type
EXPANDED_ACCESS
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath